Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.
Nurix Therapeutics, a US-based oncology therapy developer backed by pharmaceutical firm Celgene, priced its shares at $19 on Thursday and raised $209m when it went public on Friday.
The company issued 11 million shares on the Nasdaq Global Market and is trading under the ticker symbol NRIX. Nurix had initially planned to sell 8.8 million shares priced at $16 to $18.
Founded in 2009 as Kura Therapeutics, Nurix is working on small molecule drugs aimed at cancer and immune…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
